標(biāo)題: Titlebook: Biomarkers in Cancer Therapy; Liquid Biopsy Comes Hideaki Shimada Book 2019 Springer Nature Singapore Pte Ltd. 2019 Cancer screening.Exoso [打印本頁(yè)] 作者: APL 時(shí)間: 2025-3-21 18:59
書目名稱Biomarkers in Cancer Therapy影響因子(影響力)
書目名稱Biomarkers in Cancer Therapy影響因子(影響力)學(xué)科排名
書目名稱Biomarkers in Cancer Therapy網(wǎng)絡(luò)公開度
書目名稱Biomarkers in Cancer Therapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biomarkers in Cancer Therapy被引頻次
書目名稱Biomarkers in Cancer Therapy被引頻次學(xué)科排名
書目名稱Biomarkers in Cancer Therapy年度引用
書目名稱Biomarkers in Cancer Therapy年度引用學(xué)科排名
書目名稱Biomarkers in Cancer Therapy讀者反饋
書目名稱Biomarkers in Cancer Therapy讀者反饋學(xué)科排名
作者: Guileless 時(shí)間: 2025-3-21 21:32 作者: 翅膀拍動(dòng) 時(shí)間: 2025-3-22 02:53 作者: 浮雕寶石 時(shí)間: 2025-3-22 05:48 作者: 吞沒 時(shí)間: 2025-3-22 10:10 作者: 沖突 時(shí)間: 2025-3-22 16:04 作者: Nausea 時(shí)間: 2025-3-22 17:09
Cell-Free DNA can be used for treatment selection, treatment outcome monitoring, residual disease detection, cancer screening in asymptomatic individuals, and tumor dynamics monitoring. In this chapter, we summarize how different ctDNA assays can be used to guide patient care and should be integrated into the cl作者: 泰然自若 時(shí)間: 2025-3-23 00:34
Specifics 1: Head and Neck Cancer and Esophageal Cancer(TAAs). We highlight new insights into the biomarkers of HNC and EC in clinical application and identify promising avenues of research in this emerging field of study, ultimately leading to improved HNC and EC patient care.作者: Hay-Fever 時(shí)間: 2025-3-23 01:57 作者: 有惡臭 時(shí)間: 2025-3-23 08:30 作者: Mangle 時(shí)間: 2025-3-23 10:19 作者: Jocose 時(shí)間: 2025-3-23 16:45 作者: Peristalsis 時(shí)間: 2025-3-23 21:30 作者: 生意行為 時(shí)間: 2025-3-24 00:19
http://image.papertrans.cn/b/image/187807.jpg作者: Anthrp 時(shí)間: 2025-3-24 05:46 作者: JAUNT 時(shí)間: 2025-3-24 07:54 作者: 袖章 時(shí)間: 2025-3-24 11:57 作者: 大漩渦 時(shí)間: 2025-3-24 15:47 作者: 柱廊 時(shí)間: 2025-3-24 21:35 作者: eustachian-tube 時(shí)間: 2025-3-24 23:46
Weitere Beispiele und Folgerungen,ly attributed to the absence of specific symptoms during early-stage cancer and the lack of reliable biomarkers. The identification of biomarkers has the potential to aid early diagnosis and prediction of recurrence and therapeutic efficacy. Biomarkers can also enable the improvement of long-term pr作者: 自作多情 時(shí)間: 2025-3-25 03:32 作者: DNR215 時(shí)間: 2025-3-25 09:06
Einige zusammengesetzte Funktionen,rly stage, effective treatment options, and prevention of recurrence. Recently, liquid biopsies, such as circulating tumor cells, circulating tumor DNA, and microRNA, have accumulating evidence that is useful for these needs..In this review, we summarize the current advance of liquid biopsies and di作者: VEN 時(shí)間: 2025-3-25 12:28
Behandlung gegebener Abbildungsaufgaben,ncer therapy, is the lack of useful biomarkers for detecting early-stage disease. Consequently, there is an urgent need to develop biomarkers that enable the detection of early-stage tumors. Emerging evidence suggests that tumor cells release substantial amounts of nucleic acids into the bloodstream作者: 閹割 時(shí)間: 2025-3-25 16:55 作者: Graduated 時(shí)間: 2025-3-25 20:31 作者: 可商量 時(shí)間: 2025-3-26 02:54 作者: Gesture 時(shí)間: 2025-3-26 05:37
Mathematisch-physikalische Bibliotheke majority of biomarkers are tumor-associated rather than tumor-specific and show elevated levels in multiple cancers. Tumor markers thus can be helpful for differential diagnosis but are not themselves diagnostic. In the field of gynecologic malignancies, biomarkers of ovarian cancer have been eage作者: 運(yùn)動(dòng)吧 時(shí)間: 2025-3-26 11:06
Mathematisch-physikalische Bibliothekd aid radiological evaluation by reflecting prognostic information and predicting the effects of treatment. The many reports on MPM blood biomarkers have focused on their utility as screening or diagnostic tests. Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) have been used作者: Triglyceride 時(shí)間: 2025-3-26 15:11
Einige zusammengesetzte Funktionen,rly stage, effective treatment options, and prevention of recurrence. Recently, liquid biopsies, such as circulating tumor cells, circulating tumor DNA, and microRNA, have accumulating evidence that is useful for these needs..In this review, we summarize the current advance of liquid biopsies and discuss the perspective.作者: 不妥協(xié) 時(shí)間: 2025-3-26 17:30
https://doi.org/10.1007/978-981-13-7295-7Cancer screening; Exosomes; Autoantibodies; Molecular targeting therapy; Precision medicine; Clinical tri作者: COLON 時(shí)間: 2025-3-26 23:48
978-981-13-7297-1Springer Nature Singapore Pte Ltd. 2019作者: 館長(zhǎng) 時(shí)間: 2025-3-27 03:26
Liquid Biopsy in Hepatocellular Carcinomarly stage, effective treatment options, and prevention of recurrence. Recently, liquid biopsies, such as circulating tumor cells, circulating tumor DNA, and microRNA, have accumulating evidence that is useful for these needs..In this review, we summarize the current advance of liquid biopsies and discuss the perspective.作者: ethnology 時(shí)間: 2025-3-27 05:26
Liquid Biopsy Diagnostics Using Extracellular Vesiclesthers. Recent studies indicated that cancer-associated EVs play pivotal roles in constructing favorable microenvironments for cancer cells through communication with various surrounding or remote cells. In fact, they induce immunosuppression, angiogenesis, and epithelial-mesenchymal transition (EMT)作者: ALE 時(shí)間: 2025-3-27 10:14
Cell-Free DNAells is termed circulating tumor DNA (ctDNA). Despite the low levels of ctDNA in normal cfDNA, advances in digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies have led to significant improvements in the sensitivity and specificity of variant detection. As a resu作者: 訓(xùn)誡 時(shí)間: 2025-3-27 15:34 作者: fixed-joint 時(shí)間: 2025-3-27 18:38
Serum Angiogenic Factors as Cancer Biomarkerstment is applied for such angiogenic tumors, many patients suffer from progressive disease and/or rapid recurrence even after multimodal treatment. Serum angiogenic factors could be useful for predicting malignant potential and monitoring treatment response in such angiogenic tumors. Here, a compreh作者: 自由職業(yè)者 時(shí)間: 2025-3-28 00:42 作者: Type-1-Diabetes 時(shí)間: 2025-3-28 02:55
Specifics 1: Head and Neck Cancer and Esophageal Cancerly attributed to the absence of specific symptoms during early-stage cancer and the lack of reliable biomarkers. The identification of biomarkers has the potential to aid early diagnosis and prediction of recurrence and therapeutic efficacy. Biomarkers can also enable the improvement of long-term pr作者: 媽媽不開心 時(shí)間: 2025-3-28 07:53
Biomarkers in Gastric Cancerincrease during early-stage carcinogenesis, so they are not useful for early diagnosis of gastric cancer. In the outpatient center after gastrectomy, however, simple biomarkers are still convenient, and serum RNA (microRNA and long noncoding RNA) biomarkers are newly emerging, as they exhibit higher作者: 刺激 時(shí)間: 2025-3-28 11:32 作者: 考得 時(shí)間: 2025-3-28 17:13
Biomarkers of Pancreatic Cancerncer therapy, is the lack of useful biomarkers for detecting early-stage disease. Consequently, there is an urgent need to develop biomarkers that enable the detection of early-stage tumors. Emerging evidence suggests that tumor cells release substantial amounts of nucleic acids into the bloodstream作者: BABY 時(shí)間: 2025-3-28 21:45
Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age urine. In comparison with conventional tissue sampling, liquid biopsy is noninvasive, safe, and easily repeatable, and these favorable characteristics have rapidly expanded its range of application to the management of lung cancer patients. Two sources of information can be obtained by liquid biops作者: Picks-Disease 時(shí)間: 2025-3-29 00:03 作者: dandruff 時(shí)間: 2025-3-29 04:29
Biomarkers of Prostate Cancerincluding Japan. Serum prostate-specific antigen (PSA) is the most widely utilized biomarker among solid cancers. During the management of prostate cancer patients, measurement of serum PSA is useful for screening, diagnosis, risk classification, assessment of treatment effect, prediction of outcome作者: Pde5-Inhibitors 時(shí)間: 2025-3-29 08:58 作者: concert 時(shí)間: 2025-3-29 13:56
Biomarkers of Malignant Pleural Mesotheliomad aid radiological evaluation by reflecting prognostic information and predicting the effects of treatment. The many reports on MPM blood biomarkers have focused on their utility as screening or diagnostic tests. Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) have been used作者: 刺穿 時(shí)間: 2025-3-29 16:12 作者: 墊子 時(shí)間: 2025-3-29 20:56
https://doi.org/10.1007/978-3-662-49359-5as atherosclerosis, and has led to identification of some autoantibodies as common markers between cancer and atherosclerotic diseases. Thus, autoantibody analysis is useful not only for the diagnosis of many early-stage diseases but also for the comprehensive interpretation of healthy or disease conditions affecting the whole body.作者: neutralize 時(shí)間: 2025-3-30 02:36
Mathematisch-physikalische Bibliothekly emerged as cancer biomarkers and are being applied to clinical practice. Genomic biomarkers with predictive values are now used to select therapeutic drugs, especially molecular-targeted drugs. In this chapter, we describe ovarian cancer biomarkers in detail. In addition, biomarkers of uterine cancer and cervical cancer are summarized.作者: chassis 時(shí)間: 2025-3-30 04:15
Mathematisch-physikalische Bibliotheke same precursor protein as soluble mesothelin; osteopontin, a glycoprotein that mediates cell–matrix interactions; and fibulin-3, an extracellular glycoprotein. A combination of the best-performing marker and highest-value marker, as determined by ongoing research, will likely improve the accuracy and rapidity of MPM diagnosis in the near future.作者: muscle-fibers 時(shí)間: 2025-3-30 10:58
